Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Primary Biliary Cirrhosis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Primary Biliary Cirrhosis - Pipeline Review, H2 2016', provides an overview of the Primary Biliary Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis - The report reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects - The report assesses Primary Biliary Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Primary Biliary Cirrhosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Primary Biliary Cirrhosis Overview 7 Therapeutics Development 8 Pipeline Products for Primary Biliary Cirrhosis - Overview 8 Primary Biliary Cirrhosis - Therapeutics under Development by Companies 9 Primary Biliary Cirrhosis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Primary Biliary Cirrhosis - Products under Development by Companies 14 Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development 15 AlbireoPharma 15 CymaBay Therapeutics, Inc. 16 Dr. Falk Pharma GmbH 17 Enanta Pharmaceuticals, Inc. 18 Genextra S.p.a. 19 GenKyoTex S.A. 20 GlaxoSmithKline Plc 21 MediGene AG 22 NGM Biopharmaceuticals, Inc. 23 Novartis AG 24 Shire Plc 25 TGV-Laboratories 26 Virobay Inc. 27 Primary Biliary Cirrhosis - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 A-4250 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 budesonide - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 EDP-305 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 FFP-104 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 GKT-831 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 GSK-2330672 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Hep-114 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 LJN-452 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 maralixibat chloride - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 MBX-8025 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 NGM-282 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 obeticholic acid - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 RhuDex - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 VBY-825 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Primary Biliary Cirrhosis - Dormant Projects 70 Primary Biliary Cirrhosis - Product Development Milestones 71 Featured News & Press Releases 71 May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC) 71 May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC 72 May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016 73 Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL 75 Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC 76 Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016 77 Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody 79 Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC 80 Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015 80 Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis 81 Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015 82 Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting 83 Aug 31, 2015: FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis 85 Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis 86 Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015 87 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List of Tables
Number of Products under Development for Primary Biliary Cirrhosis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Comparative Analysis by Unknown Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Primary Biliary Cirrhosis - Pipeline by AlbireoPharma, H2 2016 15 Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics, Inc., H2 2016 16 Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 17 Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016 18 Primary Biliary Cirrhosis - Pipeline by Genextra S.p.a., H2 2016 19 Primary Biliary Cirrhosis - Pipeline by GenKyoTex S.A., H2 2016 20 Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2016 21 Primary Biliary Cirrhosis - Pipeline by MediGene AG, H2 2016 22 Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 23 Primary Biliary Cirrhosis - Pipeline by Novartis AG, H2 2016 24 Primary Biliary Cirrhosis - Pipeline by Shire Plc, H2 2016 25 Primary Biliary Cirrhosis - Pipeline by TGV-Laboratories, H2 2016 26 Primary Biliary Cirrhosis - Pipeline by Virobay Inc., H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 32 Number of Products by Stage and Route of Administration, H2 2016 34 Number of Products by Stage and Molecule Type, H2 2016 36 Primary Biliary Cirrhosis - Dormant Projects, H2 2016 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.